RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Febrile neutropenia risk and health care costs in members receiving low-risk antineoplastic regimens with and without granulocyte colony stimulating factor primary prophylaxis support
Huang, I., Schwab, P. E., Wojcicki, S., Poonawalla, I., Ellis, JJ., & Racasa, P. (2022). Febrile neutropenia risk and health care costs in members receiving low-risk antineoplastic regimens with and without granulocyte colony stimulating factor primary prophylaxis support. Journal of managed care & specialty pharmacy, 28((3-a), Article S88.